The FDA suspends Ixchiq, the only approved chikungunya vaccine, over safety concerns, impacting its availability in the U.S.

Valneva must immediately cease U.S. shipments and sales of Ixchiq, a vaccine for chikungunya virus. The FDA recently lifted a ...

According to the vaccine's maker, Valneva, the FDA based its decision to suspend the shot on four new serious adverse events ...

HealthDay News — The US Food and Drug Administration (FDA) is suspending the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in the United States. The move comes after reports ...

A detail of a packaging of the Ixchiq chikungunya vaccine, in a pharmacy in Saint-Denis, La Réunion, is shown March 21. The ...

In a U-turn from a decision two weeks ago, the FDA – citing new safety events – said the vaccine is a "danger to health".

U.S. health authorities have suspended the license for the Ixchiq vaccine against the chikungunya virus following reports of ...

FDA suspends Ixchiq license, raising regulatory risks for Valneva. Key vaccines anchor revenue, but valuation concerns emerge ...